head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2018, vol. 24, issue1
Subject Area: Medicine
DOI: 10.5272/jimab.2018241.1928
Published online: 09 March 2018

Original article

J of IMAB. 2018 Jan-Mar;24(1):1928-1931
Antonia Kondova1ORCID logo Corresponding Autoremail, Anna Todorova1ORCID logo, Antoaneta Tsvetkova2ORCID logo, Mariana Arnaoudova3ORCID logo, Kalina Andreevska4ORCID logo, Daniela Grekova4ORCID logo,
1) Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University, Varna, Bulgaria.
2) Medical College, Medical University, Varna, Bulgaria.
3) Department of Psychiatry and Medical Psychology, Faculty of Medicine, Medical University, Varna, Bulgaria.
4) Department of Pharmaceutical Sciences, Faculty of Pharmacy, Medical University, Plovdiv, Bulgaria.

Background: Depression is the most common mental illness affecting more than 300 million people worldwide and is a significant risk factor for morbidity and mortality. In most cases, it may remain undetected in primary care. Comprehensive screening tools for diagnosing depression might facilitate early detection. As the most accessible health professionals,pharmacists can play an important role in helping to identify individuals at risk.
Objective: To differentiate individuals at risk of depression who are seeking a pharmacist consultation and are promptly directed to a psychiatrist.
Methods: Depression screening tools The Patient Health Questionnaire (PHQ-2) and (PHQ-9) were applied to 83 individuals with symptoms such as feeling down, tiredness and sleep disturbances for more than 2 weeks, who seek consultation at a pharmacy. Screening with the PHQ-2 was the first step. Patients who screen positive were further evaluated with the PHQ-9.
Results: In 70% of the individuals, the PHQ-2 test was positive. After completing PHQ-9, it was found that approximately 55% out of them had indications of mild to moderate depression and were directed to a psychiatrist for further evaluation. Over 50% of suspected depressive individuals had a concomitant chronic disease.
Conclusion: Screening for depression should be a routine part of healthcare. Particular attention should be paid to patients with comorbid chronic illnesses, as depression often remains hidden, thus leading to more difficult diagnosis and treatment. Screening would also increase the recognition of depression in patients who have few emotional symptoms but many somatic ones.

Keywords: depression, screening, Patient Health Questionnaire, community pharmacy, cardiovascular diseases,

pdf - Download FULL TEXT /PDF 778 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Kondova A, Todorova A, Tsvetkova A, Arnaoudova M, Andreevska K, Grekova D. Screening and risk assessment for depression in community pharmacy- Pilot study. J of IMAB. 2018 Jan-Mar;24(1):1928-1931. DOI: 10.5272/jimab.2018241.1928

Corresponding AutorCorrespondence to: Antoniya Kondova, Department Pharmaceutical Sciences, Faculty of pharmacy, Medical University, Varna; 84, Tzar Osvoboditel Str., 9000 Varna, Bulgaria; E-mail: antoniakondova@mail.bg

1. Eurostat. Mental health and related issues statistics. Data extracted in September 2017. [Internet]
2. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: WHO Press, 2008. [Internet]
3. O’Reilly CL, Wong E, Chen TF. A feasibility study of community pharmacists performing depression screening services. Res Social Adm Pharm. 2015 May-Jun;11(3):364-81. [PubMed] [CrossRef]
4. Rubiero-Valera M, Chen TF, O’Reilly CL. New roles for Pharmacists in Community Mental Health Care: A Narrative Review. Int J Environ Res Public Health. 2014 Oct;11(10):10967-90. [PubMed] [CrossRef]
5. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999 Nov;282(18):1737-44. [PubMed] [CrossRef]
6. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003 Nov;41(11):1284-92. [PubMed] [CrossRef]
7. Maurer DM. Screening for depression. Am Fam Physician. 2012 Jan;85(2):139-44. [PubMed]
8. Kocalevent RD, Hinz A, Brahler E. Standardization of the depression screener patient health questionnaire (PHQ-9) in the general population. Gen Hosp Psychiatry. 2013 Sep-Oct;35(5):551-5.  [PubMed] [CrossRef]
9. Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in the Primary Care Population. Ann Fam Med. 2010 Jul-Aug;8(4):348-53. [PubMed] [CrossRef]
10. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. [PubMed]
11. Pinto-Meza A, Serrano-Blanco A, Penarrubia MT, Blanco E, Haro JM. Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? J Gen Intern Med. 2005 Aug;20(8):738-42. [PubMed] [CrossRef]
12. Beard C, Hsu KJ, Rifkin LS, Busch AB, Bjorgvinsson T. Validation of the PHQ-9 in a psychiatric sample. J Affect Disord. 2016 Mar;193:267-73. [PubMed] [CrossRef]
13. Angst J, Gamma A, Gastpar M, Lepine JP, Mendlewicz J, Tylee A. Gender differences in depression. Eur Arch Psychiatry Clin Neurosci. 2002 Oct;252(5):201-9.[PubMed] [CrossRef]
14. Kessler RC, Birnbaum H, Bromet E, Hwang I, Sampson N, Shahly V. Age differences in major depression: results from the National Comorbidity Survey replication (NCS9R). Psychol Med. 2010 Feb;40(2):225-37. [PubMed] [CrossRef]
15. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry. 2007 Mar-Apr;29(2):147-55. [PubMed] [CrossRef]
16. O'Neil A, Williams ED, Stevenson CE, Oldenburg B, Berk M, Sanderson K. Co-morbid cardiovascular disease and depression: sequence of disease onset is linked to mental but not physical self-rated health. Results from a cross-sectional, population-based study. Soc Psychiatry Psychiatr Epidemiol. 2012 Jul;47(7):1145-51. [PubMed] [CrossRef]
17. Haddad M, Walters P, Phillips R, Tsakok J, Williams P, Mann A, et al. Detecting depression in patients with coronary heart disease: a diagnostic evaluation of the PHQ-9 and HADS-D in primary care, findings from the UPBEAT-UK study. PLoS One. 2013 Oct;8(10):e78493. [PubMed] [CrossRef]
18. Katon W, Fan MY, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. J Gen Intern Med. 2008 Oct;23(10):1571-5. [PubMed] [CrossRef]
19. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006 Nov;23(11):1165-73. [PubMed] [CrossRef]
20. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008 Dec;31(12):2383-90. [PubMed] [CrossRef]
21. Schmidt do Prado-Lima PA. Medical comorbidities and functioning in depression: a clinical perspective. Medicographia. 2014; 36(4):464-469.

Received: 07 December 2017
Published online: 09 March 2018

back to Online Journal